Literature DB >> 7188643

Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis.

M G Ziegler, B R Brooks, C R Lake, J H Wood, S J Enna.   

Abstract

Patients with amyotrophic lateral sclerosis have increased levels of the neutrotransmitter norepinephrine in blood and cerebrospinal fluid and depressed levels of the inhibitory neurotransmitter gamma-aminobutyric acid in cerebrospinal fluid. These neurochemical alterations are most marked in patients bedridden with advanced disease, appear interrelated, and lead to cardiovascular alterations in patients with amyotrophic lateral sclerosis.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7188643     DOI： 10.1212/wnl.30.1.98

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Immunology of amyotrophic lateral sclerosis.

Authors:  N R Cashman; M E Gurney; J P Antel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Hyposensitivity of peripheral α-adrenoceptors in respiratordependent amyotrophic lateral sclerosis assessed by intravenous norepinephrine infusion.

Authors:  T Shimizu; H Hayashi; M Hayashi; S Kato; H Tanabe
Journal:  Clin Auton Res       Date:  1995-06       Impact factor: 4.435

3.  Relationship between respiratory failure and plasma noradrenaline levels in amyotrophic lateral sclerosis.

Authors:  A Yamashita; Y Koike; A Takahashi; M Hirayama; N Murakami; G Sobue
Journal:  Clin Auton Res       Date:  1997-08       Impact factor: 4.435

4.  Herpes simplex encephalitis presenting as the sick sinus syndrome.

Authors:  S Pollock; H Reid; P Klapper; R A Metcalfe; N Ahmed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

5.  Microneurographic analysis of muscle sympathetic nerve activity in amyotrophic lateral sclerosis.

Authors:  K Shindo; S Tsunoda; Z Shiozawa
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

Review 6.  Alterations of central GABAergic activity in neurologic and psychiatric disorders: evaluation through measurements of GABA and GAD activity in cerebrospinal fluid.

Authors:  T A Hare
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

7.  Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone.

Authors:  Jonathan A Fidler; Christopher M Treleaven; Ashley Frakes; Thomas J Tamsett; Mary McCrate; Seng H Cheng; Lamya S Shihabuddin; Brian K Kaspar; James C Dodge
Journal:  FASEB J       Date:  2011-08-29       Impact factor: 5.191

8.  Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation.

Authors:  Masaaki Nishi; Ryosuke Miyamoto; Kasane Shima; Hirokazu Miki; Hideo Terasawa; Chie Takasu; Kozo Yoshikawa; Takuro Oyama; Katsuya Tanaka; Yuishin Izumi; Mitsuo Shimada
Journal:  Int Cancer Conf J       Date:  2021-07-12

9.  Plasma and cerebrospinal fluid gamma-aminobutyric acid in neurological disorders.

Authors:  D Schmidt; W Löscher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

10.  Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis.

Authors:  Tadhg Crowley; John-Mark Fitzpatrick; Teun Kuijper; John F Cryan; Orna O'Toole; Olivia F O'Leary; Eric J Downer
Journal:  Front Cell Neurosci       Date:  2015-07-28       Impact factor: 5.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.